Overview Covering developments across all frontiers of T1D R&D, including immunotherapy, beta cell regeneration, manufactured cell therapy, and AID For decades, insulin has been a lifeline — but not a cure. Nine and a half million people worldwide live with type 1 diabetes (T1D), facing not only the worry and expense of managing the disease but the risks of hypoglycemia and complications.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile